Skip to main content
SpringerLink
Log in

Wechselwirkungen mit zielgerichtet wirksamen oralen Tumortherapeutika

  • Onkologische Pharmazie
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Van Leeuwen RWF, van Gelder T, Mathijssen RHJ, Jansman FGA (2014) Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 15:e315–326

    Article  PubMed  Google Scholar 

  2. Teo YL, Ho HK, Chan A (2015) Metabolism-related pharmacokinetic drug-drug interactions in tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 79(2):241–253. doi: 10.1111/bcp.12496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Thomas-Schoemann A, Blanchet B, Bardin C et al. (2014) Drug interactions with solid tumour-targeted therapies. Oncol Hematol 89:179–196

    Google Scholar 

  4. Lipp HP (2013) Klinisch relevante Wechselwirkungen mit peroral applizierbaren, zielgerichtet wirksamen Tumortherapeutika. Onkologe 19:870–877

    Article  Google Scholar 

  5. Tan AR, Gibbon DG, Stein MN et al. (2013) Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 6:1635–1643

    Article  Google Scholar 

  6. Van Leeuwen RWF, Peric R, Hussaarts KGAM et al. (2016) Influence of the acidic beverage cola on the absorption of erotinib in patients with non-small-cell lung cancer. J Clin Oncol 34:1309–1314

    Article  PubMed  Google Scholar 

  7. McCaleb RV, Gandhi AS, Clark SM, et al. (2016) Clinical outcomes of acid suppressive therapy use in hematology/oncology patients at an academic medical center. Ann Pharmacother 50:541–547

    Article  PubMed  Google Scholar 

  8. Mächler S, Meid AD, Send A et al. (2016) Vor, zum oder nach dem Essen? Dtsch Apotheker Z 156:2110–2117

    Google Scholar 

  9. Devriese LA, Koch KM, Mergui-Roelvink M et al}. (2014) Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Invest New Drugs 32:481–488

    Article  CAS  PubMed  Google Scholar 

  10. Chi KN, Spratlin J, Kollmannsberger C et al. (2015) Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol 55:1406–1414

    Article  CAS  PubMed  Google Scholar 

  11. Ge J, Tan BX, Chen Y et al. (2011) Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J Mol Med 89:595–602

    Article  CAS  PubMed  Google Scholar 

  12. Outeda MM, Salvador GP, Elberdin PL et al. (2016) Management of everolimus and voriconazole interaction in lung transplant patients. Ther Drug Monit 38:305–312

    Article  Google Scholar 

  13. Goebell PJ, Lipp HP (2016) Pharmakologie in der Uro-Onkologie: Fokus: Systemische Therapie des kastrationsresistenten metastasierten Prostatakarzinoms. Thieme-Refresher Onkologie 8:R25–40

    Google Scholar 

  14. Do B, Mace M, Rexwinkle A (2016) Idelalisib for treatment of B-cell malignancies. Am J Health-Syst Pharm 73:547–555

    Article  PubMed  Google Scholar 

  15. Bryant AD, Fletcher GS, Payne TH (2014) Drug interaction alert override rates in the Meaningful Use era: no evidence of progress. Appl Clin Inform 5:802–813

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. De Wit D, Guchelaar HJ, Den Hartigh J et al. (2015) Individualized dosing of tyrosine kinase inhibitors: are we there yet? Drug Discov Today 20:18–36

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Apotheke des Universitätsklinikums Tübingen, Röntgenweg 9, 72076, Tübingen, Deutschland

    Hans-Peter Lipp

Authors
  1. Hans-Peter Lipp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Peter Lipp.

Additional information

Einhaltung ethischer Richtlinien

Interessenkonflikt: H.P. Lipp gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lipp, HP. Wechselwirkungen mit zielgerichtet wirksamen oralen Tumortherapeutika. best practice onkologie 11, 42–46 (2016). https://doi.org/10.1007/s11654-016-5285-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-016-5285-4

Search

Navigation